scispace - formally typeset
Journal ArticleDOI

The interferon signature in autoimmune diseases.

Lars Rönnblom, +1 more
- 01 Mar 2013 - 
- Vol. 25, Iss: 2, pp 248-253
Reads0
Chats0
TLDR
The observed IFN signature in several autoimmune diseases is a biomarker of active disease and is investigated as a tool when selecting treatment for individual patients.
Abstract
Purpose of reviewAn increased expression of type I interferon (IFN) regulated genes (an IFN signature) has been reported in blood and tissue cells from patients with SLE and other autoimmune diseases. We review the possible mechanisms behind the IFN signature as well as clinical and therapeutic cons

read more

Citations
More filters
Posted ContentDOI

Identifying robust biomarkers of infection through an omics-based meta-analysis

TL;DR: A meta-analysis of human blood infection studies using Machine Learning revealed convergence was to pathways including the Type I interferon Signalling Pathway, Chemotaxis, Apoptotic Processes, and Inflammatory / Innate Response, particularly prevalent throughout the analysis.
Journal ArticleDOI

The expression of Ets-1 and Fli-1 is associated with interferon-inducible genes in peripheral blood mononuclear cells from Japanese patients with systemic lupus erythematosus

TL;DR: In this article , the expression of transcription factors E26 transformation-specific-1 (Ets-1), Friend leukemia insertion site (Fli-1) and type I interferon (IFN) have been implicated in systemic lupus erythematosus (SLE).
Patent

Agoniste de ppar ou agoniste de lxr à utiliser pour traiter le lupus érythémateux systémique par modulation de l'activité lap

TL;DR: The authors concerne des compositions and des methodes permettant de modifier le diagnostic and le traitement d'une maladie inflammatoire, e.g., le lupus erythemateux systemique (LES).
References
More filters
Journal ArticleDOI

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

TL;DR: Global gene expression profiling of peripheral blood mononuclear cells is used to identify distinct patterns of gene expression that distinguish most SLE patients from healthy controls, and identify a subgroup of patients who may benefit from therapies targeting the IFN pathway.
Journal ArticleDOI

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood

TL;DR: Microarray analysis of blood cells reveals that immature granulocytes may be involved in SLE pathogenesis, and the IFN signature confirms the central role of this cytokine in Sle, using oligonucleotide microarrays.
Journal ArticleDOI

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

TL;DR: Not only have genome-wide association studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.
Related Papers (5)